122 related articles for article (PubMed ID: 38623968)
1. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2.
Lai Y; Han X; Xie B; Xu Y; Yang Z; Wang D; Li W; Xie Y; Song W; Zhang X; Xia JQ; Zhang P
Cancer Sci; 2024 Apr; ():. PubMed ID: 38623968
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Wang S; Zhu Y; He H; Liu J; Xu L; Zhang H; Liu H; Liu W; Liu Y; Pan D; Chen L; Wu Q; Xu J; Gu J
Cancer Sci; 2013 Jun; 104(6):750-9. PubMed ID: 23421437
[TBL] [Abstract][Full Text] [Related]
3. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
[TBL] [Abstract][Full Text] [Related]
4. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
[TBL] [Abstract][Full Text] [Related]
5. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
[TBL] [Abstract][Full Text] [Related]
6. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.
Li X; Li Y; Lian P; Lv Q; Liu F
Hum Exp Toxicol; 2023; 42():9603271221142818. PubMed ID: 36786348
[TBL] [Abstract][Full Text] [Related]
7. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y; Chiba T; Oshima M; Koide S; Rizq O; Aoyama K; Ao J; Kaneko T; Kanzaki H; Kanayama K; Maeda T; Saito T; Nakagawa R; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Nakamoto S; Yasui S; Mikata R; Muroyama R; Kanda T; Maruyama H; Kato J; Mimura N; Ma A; Jin J; Zen Y; Otsuka M; Kaneda A; Iwama A; Kato N
Sci Rep; 2021 Nov; 11(1):21396. PubMed ID: 34725436
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation.
Gao Y; Tong M; Wong TL; Ng KY; Xie YN; Wang Z; Yu H; Loh JJ; Li M; Ma S
ACS Nano; 2023 Nov; 17(22):22240-22258. PubMed ID: 37966480
[TBL] [Abstract][Full Text] [Related]
9. CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma.
Li B; Wei S; Yang L; Peng X; Ma Y; Wu B; Fan Q; Yang S; Li X; Jin H; Tang S; Huang M; Li H; Liu J
Front Oncol; 2021; 11():657723. PubMed ID: 34485112
[TBL] [Abstract][Full Text] [Related]
10. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
[TBL] [Abstract][Full Text] [Related]
12. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
14. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
[TBL] [Abstract][Full Text] [Related]
15. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S
Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750
[TBL] [Abstract][Full Text] [Related]
16. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA CASC11 suppresses sorafenib-triggered ferroptosis via stabilizing SLC7A11 mRNA in hepatocellular carcinoma cells.
Chen F; Wang L
Discov Oncol; 2023 Aug; 14(1):145. PubMed ID: 37552314
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
Elkateb AS; Nofal S; Ali SA; Atya HB
Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
[TBL] [Abstract][Full Text] [Related]
19. RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis.
Li Z; Caron de Fromentel C; Kim W; Wang WH; Sun J; Yan B; Utturkar S; Lanman NA; Elzey BD; Yeo Y; Zhang H; Kazemian M; Levrero M; Andrisani O
Cell Death Dis; 2023 Nov; 14(11):786. PubMed ID: 38036507
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]